Session: SUN 624-646-Growth: Clinical Trials & Observational Studies
Poster Board SUN-625
Methods: All children received combined rhIGF-I/IGFBP-3 treatment of 1-2 mg/kg/d for one to two years followed by a period of no treatment and received rhIGF-I alone for one or more years. Their linear growth before any treatment, during and in between the two treatment modalities were compared. Factors that may affect linear growth i.e. age, pubertal stage and BMI are also analyzed.
Results: Annual growth rate improved from a mean of 3 cm/year (no treatment) into 6,8 and 6,3 cm/year (combined rhIGF-I/IGFBP-3 vs IGF-I alone, respectively) with growth factor treatment. Height SDS increased from -7.61 at baseline to -7.22 with combined treatment in the first year, which decreased to -7.78 after discontinuation of treatment. Height SDS increased again from -7.78 to -7.43 with IGF-I alone in one year. Although both treatments improved height velocity SDS significantly in comparison to baseline, there was no significant difference in effect between the two treatments. The growth response was partially affected by body mass index.
Conclusion: Two different forms of IGF-I promote growth in children with GHIS with a response similar to each other, however less than that observed in growth hormone deficient children with GH replacement.
Nothing to Disclose: AO, ENG, AKA, NK
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters